Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsSupportive Therapy, ToxicityProtocol groupComplicationsNeuro-OncologyradiotherapyDiseaseRadionecrosisSubgroupcerebralICD10T66MeSHRadiation InjuriesSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionBevacizumabSupportive substanceBalanced Crystalloid SolutionBevacizumabSupportive substanceBalanced Crystalloid SolutionBevacizumabSupportive substanceBalanced Crystalloid SolutionBevacizumabNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentioncurative or palliativeRisksEmetogenicity (MASCC/ESMO)PneumoniaThromboembolic Event only studiesPublicationAuthorLevin VADiseaseZerebrale Radionekrose, nach Therapie mit DexamethasonOriginDepartment of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TexasProtocols in Revision 1 protocol foundProtocols under revision.Bevacizumab 7.5, Radionecrosis (PID2138 V1.0)
